Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) was the target of a large decline in short interest in August. As of August 31st, there was short interest totalling 36,300 shares, a decline of 6.7% from the July 31st total of 38,900 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average daily volume of 30,000 shares, the short-interest ratio is presently 1.2 days.
In other news, Director Leonard Sank acquired 25,000 shares of Oramed Pharmaceuticals stock in a transaction dated Monday, September 9th. The shares were acquired at an average cost of $2.92 per share, with a total value of $73,000.00. Following the purchase, the director now directly owns 364,999 shares of the company’s stock, valued at approximately $1,065,797.08. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders bought a total of 50,817 shares of company stock worth $164,009 over the last ninety days. Corporate insiders own 20.50% of the company’s stock.
An institutional investor recently bought a new position in Oramed Pharmaceuticals stock. Jane Street Group LLC purchased a new position in shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 43,212 shares of the biotechnology company’s stock, valued at approximately $155,000. Jane Street Group LLC owned approximately 0.25% of Oramed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 4.83% of the stock is owned by hedge funds and other institutional investors.
Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings results on Wednesday, July 10th. The biotechnology company reported ($0.23) EPS for the quarter, hitting the consensus estimate of ($0.23). The firm had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.71 million. Oramed Pharmaceuticals had a negative return on equity of 56.15% and a negative net margin of 568.43%. On average, sell-side analysts anticipate that Oramed Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.
ORMP has been the topic of several research analyst reports. LADENBURG THALM/SH SH initiated coverage on Oramed Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $7.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Oramed Pharmaceuticals in a research note on Wednesday, June 19th. Finally, ValuEngine raised Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
See Also: Are FAANG stocks a good investment?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.